Kendall Capital Partners
VC Fund
Boston, United States
Kendall Capital Partners is an early-stage venture capital firm.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Kendall Capital Partners invests in
Stages Kendall Capital Partners invests in
Countries Kendall Capital Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Zhu
|
|||
Investment Focus
Industry
- Health Care 6 (60%)
- Biotechnology 5 (50%)
- Medical 3 (30%)
- Health Diagnostics 2 (20%)
- Diabetes 1 (10%)
Stage
- Venture - Series Unknown 5 (50%)
- Series A 3 (30%)
- Funding Round 1 (10%)
- Convertible Note 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Zhu
Founding Partner
|
Founding Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rejuvenate Bio
|
Rejuvenate Bio is a biotechnology company that develops novel gene therapies for dogs. The company's therapy provides a solution for the mitral valve disease to stop the progression of heart failure in dogs, thus providing pets with extended overall health and maximal lifespan. It was founded in 2017 and is based in San Diego, CA. | $6M / Venture - Series Unknown / Jun 08, 2026 | |
Centivax
|
Centivax is a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services. | $37M / Venture - Series Unknown / Mar 30, 2026 | |
|
Centivax
|
Centivax is a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services. | $45M / Series A / Jul 08, 2025 | |
EpiBone
|
EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superiorbone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. | Convertible Note / Nov 08, 2024 | |
Omnipulse Biosciences
|
Omnipulse Biosciences offers single injection quantities suitable for clinical trials and commercial distribution to low-income countries | $7M / Venture - Series Unknown / Dec 21, 2023 | |
|
EpiBone
|
EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superiorbone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. | $18.5M / Dec 27, 2022 | |
|
EpiBone
|
EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superiorbone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. | Venture - Series Unknown / Nov 26, 2022 | |
Eyenuk
|
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first product, the EyeArt AI Eye Screening System, is the most extensively validated AItechnology for autonomous detection of diabetic retinopathy. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. | $26M / Series A / Oct 17, 2022 | |
Bilayer Therapeutics
|
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. | $2M / Venture - Series Unknown / Apr 28, 2021 | |
|
Rejuvenate Bio
|
Rejuvenate Bio is a biotechnology company that develops novel gene therapies for dogs. The company's therapy provides a solution for the mitral valve disease to stop the progression of heart failure in dogs, thus providing pets with extended overall health and maximal lifespan. It was founded in 2017 and is based in San Diego, CA. | $14.6M / Series A / Apr 12, 2021 |
Co-Investors
AXA Investment Managers
2 deals together
Digitalis Ventures
2 deals together
EMV Capital
2 deals together
THE CATALYTIC IMPACT FOUNDATION (CIF)
2 deals together
VCapital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Kendall Capital Partners invest in?
Kendall Capital Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kendall Capital Partners?
Public channels for Kendall Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kendall Capital Partners?
The team at Kendall Capital Partners includes David Zhu (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
